Antiplatelet therapy: targeting the TxA2 pathway

Journal of Cardiovascular Translational Research
P FontanaJ-L Reny

Abstract

The thromboxane (Tx) A2 pathway is a major contributor to the amplification of the initial platelet activation process. TxA2 mediates its effect through the thromboxane prostanoid (TP) receptor that is expressed not only in platelets, but also in endothelial cells, macrophages, and monocytes, and thus contributes to the development of atherosclerotic lesions. The TxA2 pathway is therefore a major target in the treatment of cardiovascular disease. Aspirin-the most widely used antiplatelet drug-is very effective at inhibiting platelet-derived TxA2 synthesis. However, aspirin's effects can be overcome by several other soluble agonists such as isoprostanes, which are aspirin-insensitive ligands of the TP receptor that are preferentially produced in diabetes mellitus. Other drugs, with either inhibitory effects on Tx synthase or antagonist effects on TP, have been developed with the hope of providing a better, more complete inhibition of the TxA2 pathway.

References

Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Dec 1, 1985·Circulation·G A FitzGeraldA K Pedersen
Nov 15, 1994·Annals of the New York Academy of Sciences·S Narumiya
May 5, 1994·The New England Journal of Medicine·C Patrono
Mar 1, 1993·Stroke; a Journal of Cerebral Circulation·C M HelgasonL D Brace
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Bianca RoccaCarlo Patrono
Sep 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·N V ChandrasekharanDaniel L Simmons
Oct 12, 2004·European Heart Journal·Gian Gastone Neri SerneriUNKNOWN Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group
Jan 1, 2005·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Regina Botting, Samir S Ayoub
Apr 22, 2005·The New England Journal of Medicine·Göran K Hansson
May 17, 2005·Journal of Thrombosis and Haemostasis : JTH·A D MichelsonUNKNOWN Working Group on Aspirin Resistance
Jun 28, 2005·Journal of Thrombosis and Haemostasis : JTH·P GaussemJ-N Fiessinger
Dec 2, 2005·The New England Journal of Medicine·Carlo PatronoColin Baigent
Feb 7, 2006·European Journal of Pharmacology·Stéphanie RolinJean-Michel Dogné
Sep 6, 2006·Thrombosis and Haemostasis·Pierre FontanaPascale Gaussem
Jan 24, 2007·American Heart Journal·Marcel M C HovensMenno V Huisman
Feb 28, 2007·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·P Fontana, J-L Reny
May 15, 2007·Circulation Research·Telly A Meadows, Deepak L Bhatt
Jun 9, 2007·Journal of Proteome Research·Antonio J López-FarréCarlos Macaya
Sep 28, 2007·Current Pharmaceutical Design·J A Coppinger, P B Maguire
Nov 28, 2007·Annual Review of Pathology·Göran K HanssonCecilia Söderberg-Nauclér
Feb 26, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Guy A Zimmerman, Andrew S Weyrich
Apr 1, 2008·Pharmacology & Therapeutics·Norimichi Nakahata
Mar 19, 2009·Annals of Internal Medicine·UNKNOWN US Preventive Services Task Force
Dec 1, 2009·Journal of Thrombosis and Haemostasis : JTH·A A KondkarP F Bray
Jan 12, 2010·Thrombosis and Haemostasis·Petra J Mateos-CáceresAntonio J López-Farré
Mar 4, 2010·JAMA : the Journal of the American Medical Association·F Gerald R FowkesUNKNOWN Aspirin for Asymptomatic Atherosclerosis Trialists
Jun 15, 2010·Clinical Lipidology·Emer M Smyth
Aug 21, 2010·Journal of Thrombosis and Haemostasis : JTH·J N FiessingerUNKNOWN TAIPAD investigators

❮ Previous
Next ❯

Citations

Aug 1, 2015·Thrombosis and Haemostasis·Karin A L MüllerTobias Geisler
Mar 24, 2016·Journal of Enzyme Inhibition and Medicinal Chemistry·Max Seidy SaitoPlínio Cunha Satlher
Oct 11, 2015·Journal of Cardiovascular Translational Research·Emanuele BarbatoJennifer L Hall
Apr 9, 2016·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Yilin PanManxiang Li
Oct 25, 2016·Biochimica Et Biophysica Acta·Ming-Jie JiangLing Tian
Aug 19, 2017·International Journal of Molecular Sciences·Katalin KoltaiKalman Toth
Jun 25, 2018·Journal of the American Heart Association·Firdos Ahmad
Mar 26, 2019·Clinical and Experimental Pharmacology & Physiology·Hong YanChun-Yu Deng
Dec 19, 2015·Expert Opinion on Drug Safety·Ruby CrossDaniel H Paris
Nov 1, 2015·Journal of Cardiovascular Pharmacology and Therapeutics·Nadezhda GlezevaMark Ledwidge
Jan 23, 2020·International Journal of Molecular Sciences·Cristina Barale, Isabella Russo
Jan 27, 2017·Biomedical Reports·Xiaoyang YangFangping Chen
Jul 11, 2019·Future Medicinal Chemistry·Zhouling XieChenzhong Liao
Oct 9, 2019·Advanced Science·Gary HannonAdriele Prina-Mello
Nov 6, 2018·International Journal of Molecular Medicine·Li LiKeji Chen
Apr 2, 2021·Clinical and Experimental Pharmacology & Physiology·Run-Sheng JiangWei Wu
Aug 21, 2021·European Journal of Pharmacology·Juan HuShuangxin Liu
Jul 11, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yun-Yi YanYun-Man Li
Nov 21, 2021·Cardiovascular Drugs and Therapy·Afek KodeshLeor Perl
Dec 4, 2021·Journal of Veterinary Internal Medicine·Elizabeth A ConwayAlison E Ridyard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.